Renaissance Capital logo

Genenta Science Scheduled, Nasdaq: GNTA

Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. We have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Our technology is designed to turn TEMs, which normally have an affinity for and travel to tumors, into a “Trojan Horse” to counteract cancer progression and to prevent tumor relapse. Our technology is not target dependent, and therefore we believe it can be used as a treatment for a broad variety of cancers. Our technology incorporates the use of a lentiviral vector (LVV) that combines a therapeutic transgene sequence, or payload, with our proprietary platform. Our proprietary platform consists of (i) the Tie-2 promoter, that drives transgene sequence transcription specifically in TEMs, and (ii) miRNA-126 target sequences to downregulate transgene expression post-transcription in those cells where the Tie-2 promoter is active and the miRNA-126 is present.
more less
IPO News for Genenta Science
more
IPO Data
IPO File Date 11/10/2021
Offer Price
Price Range $10.50 - $12.50
Offer Shares (mm) 2.6
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $10.50 - $12.50
Offer Shares (mm) 2.6
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Milan, Italy
Founded 2014
Employees 4
Website www.genenta.com